Clinical Cancer Research, Vol 4, Issue 5 1243-1250, Copyright © 1998 by American Association for Cancer Research

ARTICLES

p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival

HJ Lenz, K Hayashi, D Salonga, KD Danenberg, PV Danenberg, R Metzger, D Banerjee, JR Bertino, S Groshen, LP Leichman and CG Leichman
University of Southern California/Norris Comprehensive Cancer Center, University of Southern California School of Medicine, Los Angeles 90033, USA. lenz@hsc.usc.edu

Recent studies suggest that there may be a strong correlation between the p53 status of a tumor and a patient's response to chemotherapy. Therefore, we determined p53 status in 36 patients with disseminated colorectal cancer by cDNA sequencing and immunohistochemical staining, as well as by the gene expression level of thymidylate synthase (TS), the target enzyme of 5-fluorouracil (5-FU), by reverse transcription-PCR. Ten patients (28%) experienced a clinical response to 5-FU chemotherapy. Overall, TS expression and response to chemotherapy were associated: 9 of 18 (50%) patients with TS < or = 3.0 x 10(-3) responded, compared to 1 of 18 (6%) patients with TS > 3.0 x 10(-3) (P = 0.003). p53 mutations were found in 21 of 36 patients (58%) using cDNA cycle sequencing, and p53 protein overexpression was found in 20 of 32 patients (62%) using immunohistochemistry staining. Overall p53 status and response to chemotherapy were associated: 5 of 10 (50%) patients with wild-type p53 or negative p53 staining experienced a response, but only 5 of 26 (19%) patients with mutant p53 or p53 overexpression responded. TS expression, but not expression of p53, was significantly associated with overall survival (P = 0.002). Patients with wild-type p53 had significantly lower TS levels compared to patients with mutated p53 (P = 0.044). In this study, we also present data linking specific p53 point mutations to TS expression levels and resistance to 5-FU. Although the number of patients is relatively small, these results identify p53 status and TS gene expression as associated with response in disseminated colorectal cancer; independent studies are needed to confirm these findings and to provide information leading to a better understanding of the role of 5-FU-based chemotherapy in the treatment of colorectal cancer.

This article has been cited by other articles:

				P. M. Wilson, W. Fazzone, M. J. LaBonte, J. Deng, N. Neamati, and R. D. Ladner Novel opportunities for thymidylate metabolism as a therapeutic target Mol. Cancer Ther., September 1, 2008; 7(9): 3029 - 3037. [Abstract] [Full Text] [PDF]

				R. Sharma, J. M. Hoskins, L. P. Rivory, M. Zucknick, R. London, C. Liddle, and S. J. Clarke Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients Clin. Cancer Res., February 1, 2008; 14(3): 817 - 825. [Abstract] [Full Text] [PDF]

				S. Michienzi, B. Bucci, C. Verga Falzacappa, V. Patriarca, A. Stigliano, L. Panacchia, E. Brunetti, V. Toscano, and S. Misiti 3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy J. Endocrinol., May 1, 2007; 193(2): 209 - 223. [Abstract] [Full Text] [PDF]

				M. F. Reed, W. A. Zagorski, J. A. Howington, J. T. Zilfou, and E. S. Knudsen Inhibition of retinoblastoma tumor suppressor activity by RNA interference in lung cancer lines. Ann. Thorac. Surg., July 1, 2006; 82(1): 249 - 253. [Abstract] [Full Text] [PDF]

				F. A. Sinicrope, R. L. Rego, K. C. Halling, N. R. Foster, D. J. Sargent, B. La Plant, A. J. French, C. J. Allegra, J. A. Laurie, R. M. Goldberg, et al. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin. Cancer Res., May 1, 2006; 12(9): 2738 - 2744. [Abstract] [Full Text] [PDF]

				E. Dotor, M. Cuatrecases, M. Martinez-Iniesta, M. Navarro, F. Vilardell, E. Guino, L. Pareja, A. Figueras, D. G. Mollevi, T. Serrano, et al. Tumor Thymidylate Synthase 1494del6 Genotype As a Prognostic Factor in Colorectal Cancer Patients Receiving Fluorouracil-Based Adjuvant Treatment J. Clin. Oncol., April 1, 2006; 24(10): 1603 - 1611. [Abstract] [Full Text] [PDF]

				H. T. Yip, R. Chopra, R. Chakrabarti, M. S. Veena, B. Ramamurthy, E. S. Srivatsan, and M. B. Wang Cisplatin-Induced Growth Arrest of Head and Neck Cancer Cells Correlates With Increased Expression of p16 and p53. Arch Otolaryngol Head Neck Surg, March 1, 2006; 132(3): 317 - 326. [Abstract] [Full Text] [PDF]

				J. L. Westra, H. Hollema, M. Schaapveld, I. Platteel, K. A. Oien, W. N. Keith, R. Mauritz, G. J. Peters, C. H. C. M. Buys, R. M. W. Hofstra, et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients Ann. Onc., October 1, 2005; 16(10): 1646 - 1653. [Abstract] [Full Text] [PDF]

				K. Ohrling, D. Edler, M. Hallstrom, P. Ragnhammar, and H. Blomgren Detection of Thymidylate Synthase Expression in Lymph Node Metastases of Colorectal Cancer Can Improve the Prognostic Information J. Clin. Oncol., August 20, 2005; 23(24): 5628 - 5634. [Abstract] [Full Text] [PDF]

				T. Lecomte, J.-M. Ferraz, F. Zinzindohoue, M.-A. Loriot, D.-A. Tregouet, B. Landi, A. Berger, P.-H. Cugnenc, R. Jian, P. Beaune, et al. Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy Clin. Cancer Res., September 1, 2004; 10(17): 5880 - 5888. [Abstract] [Full Text] [PDF]

				J. Boyer, E. G. McLean, S. Aroori, P. Wilson, A. McCulla, P. D. Carey, D. B. Longley, and P. G. Johnston Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan Clin. Cancer Res., March 15, 2004; 10(6): 2158 - 2167. [Abstract] [Full Text] [PDF]

				T.-L. Wang, L. A. Diaz Jr., K. Romans, A. Bardelli, S. Saha, G. Galizia, M. Choti, R. Donehower, G. Parmigiani, I.-M. Shih, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients PNAS, March 2, 2004; 101(9): 3089 - 3094. [Abstract] [Full Text] [PDF]

				S. Popat, A. Matakidou, and R. S. Houlston Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis J. Clin. Oncol., February 1, 2004; 22(3): 529 - 536. [Abstract] [Full Text] [PDF]

				Y. C. Hu, R. A. Komorowski, S. Graewin, G. Hostetter, O.-P. Kallioniemi, H. A. Pitt, and S. A. Ahrendt Thymidylate Synthase Expression Predicts the Response to 5-Fluorouracil-based Adjuvant Therapy in Pancreatic Cancer Clin. Cancer Res., September 15, 2003; 9(11): 4165 - 4171. [Abstract] [Full Text] [PDF]

				Y. Guo, E. Kotova, Z.-S. Chen, K. Lee, E. Hopper-Borge, M. G. Belinsky, and G. D. Kruh MRP8, ATP-binding Cassette C11 (ABCC11), Is a Cyclic Nucleotide Efflux Pump and a Resistance Factor for Fluoropyrimidines 2',3'-Dideoxycytidine and 9'-(2'-Phosphonylmethoxyethyl)adenine J. Biol. Chem., August 8, 2003; 278(32): 29509 - 29514. [Abstract] [Full Text] [PDF]

				M. van Rijnsoever, H. Elsaleh, D. Joseph, K. McCaul, and B. Iacopetta CpG Island Methylator Phenotype Is an Independent Predictor of Survival Benefit from 5-Fluorouracil in Stage III Colorectal Cancer Clin. Cancer Res., August 1, 2003; 9(8): 2898 - 2903. [Abstract] [Full Text] [PDF]

				J. R. Bertino and D. Banerjee Is the Measurement of Thymidylate Synthase to Determine Suitability for Treatment with 5-Fluoropyrimidines Ready for Prime Time? Clin. Cancer Res., April 1, 2003; 9(4): 1235 - 1239. [Full Text] [PDF]

				M. Gonen, A. Hummer, A. Zervoudakis, D. Sullivan, Y. Fong, D. Banerjee, D. Klimstra, C. Cordon-Cardo, J. Bertino, and N. Kemeny Thymidylate Synthase Expression in Hepatic Tumors Is a Predictor of Survival and Progression in Patients With Resectable Metastatic Colorectal Cancer J. Clin. Oncol., February 1, 2003; 21(3): 406 - 412. [Abstract] [Full Text] [PDF]

				M. Derenzini, L. Montanaro, A. Chilla, E. Tosti, C. Ceccarelli, F. Dall'Olio, D. Ofner, and D. Trere Evaluation of Thymidylate Synthase Protein Expression by Western Blotting and Immunohistochemistry on Human Colon Carcinoma Xenografts in Nude Mice J. Histochem. Cytochem., December 1, 2002; 50(12): 1633 - 1640. [Abstract] [Full Text] [PDF]

				M.-C. Etienne, M. Chazal, P. Laurent-Puig, N. Magne, C. Rosty, J.-L. Formento, M. Francoual, P. Formento, N. Renee, E. Chamorey, et al. Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic Analyses J. Clin. Oncol., June 15, 2002; 20(12): 2832 - 2843. [Abstract] [Full Text] [PDF]

				D. B. Longley, J. Boyer, W. L. Allen, T. Latif, P. R. Ferguson, P. J. Maxwell, U. McDermott, M. Lynch, D. P. Harkin, and P. G. Johnston The Role of Thymidylate Synthase Induction in Modulating p53-regulated Gene Expression in Response to 5-Fluorouracil and Antifolates Cancer Res., May 1, 2002; 62(9): 2644 - 2649. [Abstract] [Full Text] [PDF]

				C. Allegra Thymidylate Synthase Levels: Prognostic, Predictive, or Both? J. Clin. Oncol., April 1, 2002; 20(7): 1711 - 1713. [Full Text] [PDF]

				D. Edler, B. Glimelius, M. Hallstrom, A. Jakobsen, P. G. Johnston, I. Magnusson, P. Ragnhammar, and H. Blomgren Thymidylate Synthase Expression in Colorectal Cancer: A Prognostic and Predictive Marker of Benefit From Adjuvant Fluorouracil-Based Chemotherapy J. Clin. Oncol., April 1, 2002; 20(7): 1721 - 1728. [Abstract] [Full Text] [PDF]

				M. M. Borner, D. Dietrich, R. Stupp, R. Morant, H. Honegger, M. Wernli, R. Herrmann, B. C. Pestalozzi, P. Saletti, S. Hanselmann, et al. Phase II Study of Capecitabine and Oxaliplatin in First- and Second-Line Treatment of Advanced or Metastatic Colorectal Cancer J. Clin. Oncol., April 1, 2002; 20(7): 1759 - 1766. [Abstract] [Full Text] [PDF]

				Y. Shirota, J. Stoehlmacher, J. Brabender, Y.-P. Xiong, H. Uetake, K. D. Danenberg, S. Groshen, D. D. Tsao-Wei, P. V. Danenberg, and H.-J. Lenz ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy J. Clin. Oncol., December 1, 2001; 19(23): 4298 - 4304. [Abstract] [Full Text]

				J. L. Grem, K. D. Danenberg, K. Behan, A. Parr, L. Young, P. V. Danenberg, D. Nguyen, J. Drake, A. Monks, and C. J. Allegra Thymidine Kinase, Thymidylate Synthase, and Dihydropyrimidine Dehydrogenase Profiles of Cell Lines of the National Cancer Institute's Anticancer Drug Screen Clin. Cancer Res., April 1, 2001; 7(4): 999 - 1009. [Abstract] [Full Text]

				E. Villafranca, Y. Okruzhnov, M. A. Dominguez, J. Garcia-Foncillas, I. Azinovic, E. Martinez, J. J. Illarramendi, F. Arias, R. Martinez-Monge, E. Salgado, et al. Polymorphisms of the Repeated Sequences in the Enhancer Region of the Thymidylate Synthase Gene Promoter May Predict Downstaging After Preoperative Chemoradiation in Rectal Cancer J. Clin. Oncol., March 15, 2001; 19(6): 1779 - 1786. [Abstract] [Full Text] [PDF]

				C.-T. Hsueh, Y.-C. Wu, and G. K. Schwartz UCN-01 Suppresses E2F-1 Mediated by Ubiquitin-proteasome-dependent Degradation Clin. Cancer Res., March 1, 2001; 7(3): 669 - 674. [Abstract] [Full Text]

				C. Aschele, D. Debernardis, G. Tunesi, F. Maley, and A. Sobrero Thymidylate Synthase Protein Expression in Primary Colorectal Cancer Compared with the Corresponding Distant Metastases and Relationship with the Clinical Response to 5-Fluorouracil Clin. Cancer Res., December 1, 2000; 6(12): 4797 - 4802. [Abstract] [Full Text]

				R. D. Ladner, F. J. Lynch, S. Groshen, Y. P. Xiong, A. Sherrod, S. J. Caradonna, J. Stoehlmacher, and H.-J. Lenz dUTP Nucleotidohydrolase Isoform Expression in Normal and Neoplastic Tissues: Association with Survival and Response to 5-Fluorouracil in Colorectal Cancer Cancer Res., July 1, 2000; 60(13): 3493 - 3503. [Abstract] [Full Text]

				D. Banerjee, R. Gorlick, A. Liefshitz, K. Danenberg, P. C. Danenberg, P. V. Danenberg, D. Klimstra, S. Jhanwar, C. Cordon-Cardo, Y. Fong, et al. Levels of E2F-1 Expression Are Higher in Lung Metastasis of Colon Cancer As Compared with Hepatic Metastasis and Correlate with Levels of Thymidylate Synthase Cancer Res., May 1, 2000; 60(9): 2365 - 2367. [Abstract] [Full Text]

				A. Cabelguenne, H. Blons, I. de Waziers, F. Carnot, A.-M. Houllier, T. Soussi, D. Brasnu, P. Beaune, O. Laccourreye, and P. Laurent-Puig p53 Alterations Predict Tumor Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Series J. Clin. Oncol., April 7, 2000; 18(7): 1465 - 1473. [Abstract] [Full Text] [PDF]

				D. Edler, M. Hallström, P. G. Johnston, I. Magnusson, P. Ragnhammar, and H. Blomgren Thymidylate Synthase Expression: An Independent Prognostic Factor for Local Recurrence, Distant Metastasis, Disease-free and Overall Survival in Rectal Cancer Clin. Cancer Res., April 1, 2000; 6(4): 1378 - 1384. [Abstract] [Full Text]

				D. Edler, U. Kressner, P. Ragnhammar, P. G. Johnston, I. Magnusson, B. Glimelius, L. Påhlman, G. Lindmark, and H. Blomgren Immunohistochemically Detected Thymidylate Synthase in Colorectal Cancer: An Independent Prognostic Factor of Survival Clin. Cancer Res., February 1, 2000; 6(2): 488 - 492. [Abstract] [Full Text]

				Y. Ishikawa, T. Kubota, Y. Otani, M. Watanabe, T. Teramoto, K. Kumai, M. Kitajima, T. Takechi, H. Okabe, and M. Fukushima Dihydropyrimidine Dehydrogenase Activity and Messenger RNA Level May Be Related to the Antitumor Effect of 5-Fluorouracil on Human Tumor Xenografts in Nude Mice Clin. Cancer Res., April 1, 1999; 5(4): 883 - 889. [Abstract] [Full Text] [PDF]

				M. R. Posner, P. G. Johnston, R. B. Tishler, J. Andersen, M. Fiorentino, P. M. Busse, L. A. Cavacini, A. D. Colevas, J. Clark, and C. M. Norris The Prognostic Value of Thymidylate Synthase and p53 Expression in Patients Treated with Induction Chemotherapy for Squamous Cell Carcinoma of the Head and Neck Oncologist, December 1, 1998; 3(6): 424 - 431. [Abstract] [Full Text]